Polyamine Catabolism in Platinum Drug Action

铂类药物作用中的多胺分解代谢

基本信息

  • 批准号:
    7555372
  • 负责人:
  • 金额:
    $ 30.16万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-04-01 至 2010-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Platinum (Pt) drugs play a significant role in the clinical management of cancer. The antitumor response caused by Pt agents is believed to be due to Pt-DNA adduct formation. Recent, validated microarray data from this laboratory indicate that both oxaliplatin and cisplatin potently induce gene expression of the key polyamine (PA) catabolic enzyme, spermidine/ spermine N1-acetyltransferase (SSAT), in cultured A2780 ovarian carcinoma cells. Other PA catabolic enzymes were also found to be induced. Since induction of SSAT by other means has been previously linked to growth inhibition and apoptosis, it is likely that the 10-15-fold induction in mRNA seen with oxaliplatin contributes to overall drug action. At clinically achievable drug concentrations and exposure times, oxaliplatin produces a significant induction of SSAT activity due to transcriptional activation of the SSAT gene. The combination of oxaliplatin and N1, N11-diethylnorspermine (DENSPM), a PA analog known to transcriptionally and post-transcriptionally activate SSAT expression, synergistically induces massive amounts of SSAT mRNA and activity and a greater than additive growth inhibition. DENSPM has been shown to be clinically safe and continues to under go clinical testing. The overall goals of this application are to investigate the role of SSAT induction in Pt drug action and to devise therapeutic strategies that exploit synergistic drug interactions at the level of SSAT induction. Thus, specific aims propose to: (1) characterize Pt drug effects alone and in combination with DENSPM on PA metabolism and growth in ovarian cancer cells and Pt drug resistant variants, (2) investigate the mechanistic relationship between PA catabolism and Pt drug action (3) assess the therapeutic potential of the Pt-drug /DENSPM combination against human tumor xenografts. Studies will use biochemical and molecular techniques, novel mouse models, and human tumor xenografts. Overall, we expect to define mechanism-based rationale for clinical trials evaluating the combined use of Pt-drugs and DENSPM.
描述(由申请人提供):铂(Pt)药物在癌症的临床治疗中发挥着重要作用。 Pt 剂引起的抗肿瘤反应被认为是由于 Pt-DNA 加合物的形成。该实验室最近经过验证的微阵列数据表明,奥沙利铂和顺铂均可有效诱导培养的 A2780 卵巢癌细胞中关键多胺 (PA) 分解代谢酶、亚精胺/精胺 N1-乙酰转移酶 (SSAT) 的基因表达。还发现其他 PA 分解代谢酶也被诱导。由于之前通过其他方式诱导 SSAT 与生长抑制和细胞凋亡有关,因此奥沙利铂观察到的 mRNA 10-15 倍诱导可能有助于整体药物作用。在临床可达到的药物浓度和暴露时间下,奥沙利铂由于 SSAT 基因的转录激活而显着诱导 SSAT 活性。奥沙利铂和 N1, N11-二乙基去甲精胺 (DENSPM) 的组合(一种 PA 类似物,已知可在转录和转录后激活 SSAT 表达),协同诱导大量的 SSAT mRNA 和活性,并产生大于加性的生长抑制。 DENSPM 已被证明具有临床安全性,并将继续接受临床测试。本申请的总体目标是研究 SSAT 诱导在 Pt 药物作用中的作用,并设计在 SSAT 诱导水平上利用协同药物相互作用的治疗策略。因此,具体目标是:(1) 表征单独的 Pt 药物以及与 DENSPM 组合对卵巢癌细胞和 Pt 耐药变体中 PA 代谢和生长的影响,(2) 研究 PA 分解代谢和 Pt 药物作用之间的机制关系 (3) 评估 Pt-药物/DENSPM 组合对人类肿瘤异种移植物的治疗潜力。研究将使用生化和分子技术、新型小鼠模型和人类肿瘤异种移植物。总体而言,我们期望为评估 Pt 药物和 DENSPM 联合使用的临床试验定义基于机制的基本原理。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.
  • DOI:
    10.1007/s00280-010-1334-9
  • 发表时间:
    2011-02
  • 期刊:
  • 影响因子:
    3
  • 作者:
    Tummala, Ramakumar;Diegelman, Paula;Hector, Suzanne;Kramer, Debora L.;Clark, Kimberly;Zagst, Patricia;Fetterly, Gerald;Porter, Carl W.;Pendyala, Lakshmi
  • 通讯作者:
    Pendyala, Lakshmi
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LAKSHMI PENDYALA其他文献

LAKSHMI PENDYALA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LAKSHMI PENDYALA', 18)}}的其他基金

Pharmacokinetics
药代动力学
  • 批准号:
    7714429
  • 财政年份:
    2008
  • 资助金额:
    $ 30.16万
  • 项目类别:
Polyamine Catabolism in Platinum Drug Action
铂类药物作用中的多胺分解代谢
  • 批准号:
    7046818
  • 财政年份:
    2005
  • 资助金额:
    $ 30.16万
  • 项目类别:
Polyamine Catabolism in Platinum Drug Action
铂类药物作用中的多胺分解代谢
  • 批准号:
    6927581
  • 财政年份:
    2005
  • 资助金额:
    $ 30.16万
  • 项目类别:
Polyamine Catabolism in Platinum Drug Action
铂类药物作用中的多胺分解代谢
  • 批准号:
    7213399
  • 财政年份:
    2005
  • 资助金额:
    $ 30.16万
  • 项目类别:
Polyamine Catabolism in Platinum Drug Action
铂类药物作用中的多胺分解代谢
  • 批准号:
    7355528
  • 财政年份:
    2005
  • 资助金额:
    $ 30.16万
  • 项目类别:
Molecular Correlates--Oxaliplatin/5FU/XRT, Esophageal CA
分子相关性--奥沙利铂/5FU/XRT,食管CA
  • 批准号:
    6515119
  • 财政年份:
    2001
  • 资助金额:
    $ 30.16万
  • 项目类别:
Molecular Correlates--Oxaliplatin/5FU/XRT, Esophageal CA
分子相关性--奥沙利铂/5FU/XRT,食管CA
  • 批准号:
    6339963
  • 财政年份:
    2001
  • 资助金额:
    $ 30.16万
  • 项目类别:
Pharmacokinetics
药代动力学
  • 批准号:
    8375986
  • 财政年份:
  • 资助金额:
    $ 30.16万
  • 项目类别:
Pharmacokinetics
药代动力学
  • 批准号:
    7826849
  • 财政年份:
  • 资助金额:
    $ 30.16万
  • 项目类别:
Pharmacokinetics
药代动力学
  • 批准号:
    8078047
  • 财政年份:
  • 资助金额:
    $ 30.16万
  • 项目类别:

相似海外基金

The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
  • 批准号:
    EP/Z000920/1
  • 财政年份:
    2025
  • 资助金额:
    $ 30.16万
  • 项目类别:
    Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
  • 批准号:
    FT230100276
  • 财政年份:
    2024
  • 资助金额:
    $ 30.16万
  • 项目类别:
    ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
  • 批准号:
    MR/X024261/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.16万
  • 项目类别:
    Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
  • 批准号:
    DE240100388
  • 财政年份:
    2024
  • 资助金额:
    $ 30.16万
  • 项目类别:
    Discovery Early Career Researcher Award
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
  • 批准号:
    2232190
  • 财政年份:
    2023
  • 资助金额:
    $ 30.16万
  • 项目类别:
    Continuing Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
  • 批准号:
    2337595
  • 财政年份:
    2023
  • 资助金额:
    $ 30.16万
  • 项目类别:
    Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
  • 批准号:
    23K17514
  • 财政年份:
    2023
  • 资助金额:
    $ 30.16万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Analysis of thermoregulatory mechanisms by the CNS using model animals of female-dominant infectious hypothermia
使用雌性传染性低体温模型动物分析中枢神经系统的体温调节机制
  • 批准号:
    23KK0126
  • 财政年份:
    2023
  • 资助金额:
    $ 30.16万
  • 项目类别:
    Fund for the Promotion of Joint International Research (International Collaborative Research)
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
  • 批准号:
    2842926
  • 财政年份:
    2023
  • 资助金额:
    $ 30.16万
  • 项目类别:
    Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
  • 批准号:
    NC/X001644/1
  • 财政年份:
    2023
  • 资助金额:
    $ 30.16万
  • 项目类别:
    Training Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了